190 related articles for article (PubMed ID: 16987045)
1. Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
Khanlou H; Farthing C
AIDS Patient Care STDS; 2006 Sep; 20(9):604-5. PubMed ID: 16987045
[No Abstract] [Full Text] [Related]
2. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
3. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
[TBL] [Abstract][Full Text] [Related]
4. Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
Kuritzkes DR
J Infect Dis; 2005 Dec; 192(11):1867-8. PubMed ID: 16267755
[No Abstract] [Full Text] [Related]
5. Failure of tenofovir + abacavir + 3TC combination; full report published, more insight.
James JS
AIDS Treat News; 2005; (416):5-6. PubMed ID: 16388545
[TBL] [Abstract][Full Text] [Related]
6. Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
Ross L; Elion R; Lanier R; Dejesus E; Cohen C; Redfield RR; Gathe JC; Hsu RK; Yau L; Paulsen D; Ha B;
AIDS Res Hum Retroviruses; 2009 Jul; 25(7):665-72. PubMed ID: 19563238
[TBL] [Abstract][Full Text] [Related]
7. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naïve subjects: a 48-week pilot study.
Elion R; Cohen C; DeJesus E; Redfield R; Gathe J; Hsu R; Yau L; Ross L; Ha B; Lanier RE; Scott T;
HIV Clin Trials; 2006; 7(6):324-33. PubMed ID: 17208898
[TBL] [Abstract][Full Text] [Related]
8. Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
Feinberg J
AIDS Clin Care; 2003 Nov; 15(11):94. PubMed ID: 14682272
[No Abstract] [Full Text] [Related]
9. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
Albrecht H
AIDS Clin Care; 2008 Apr; 20(4):28. PubMed ID: 19271262
[No Abstract] [Full Text] [Related]
10. Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.
d'Ettorre G; Zaffiri L; Ceccarelli G; Andreotti M; Massetti AP; Vella S; Mastroianni CM; Vullo V
HIV Clin Trials; 2007; 8(3):182-8. PubMed ID: 17621465
[TBL] [Abstract][Full Text] [Related]
11. Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir.
TreatmentUpdate; 2004 Mar; 16(2):2-3. PubMed ID: 17219666
[No Abstract] [Full Text] [Related]
12. Investigating new antiretroviral combinations.
Carr A
J Infect Dis; 2006 Jun; 193(12):1742; author reply 1742-3. PubMed ID: 16703520
[No Abstract] [Full Text] [Related]
13. Viread, Epivir and Ziagen combination: failure in naïve patients with a once-daily regimen.
Berger DS
Posit Aware; 2003; 14(5):51-2. PubMed ID: 14679946
[No Abstract] [Full Text] [Related]
14. Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.
Khanlou H; Yeh V; Guyer B; Farthing C
AIDS Patient Care STDS; 2005 Mar; 19(3):135-40. PubMed ID: 15798380
[TBL] [Abstract][Full Text] [Related]
15. Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Stephan C; Dauer B; Khaykin P; Stuermer M; Gute P; Klauke S; Staszewski S
Curr HIV Res; 2009 May; 7(3):320-6. PubMed ID: 19442129
[TBL] [Abstract][Full Text] [Related]
16. [Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Bayonne Kombo ES; Gathse A
Med Mal Infect; 2013 Mar; 43(3):134-5. PubMed ID: 23434355
[No Abstract] [Full Text] [Related]
17. Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.
Grant PM; Tierney C; Budhathoki C; Daar ES; Sax PE; Collier AC; Fischl MA; Zolopa AR; Balamane M; Katzenstein D
HIV Clin Trials; 2013; 14(6):284-91. PubMed ID: 24334181
[TBL] [Abstract][Full Text] [Related]
18. Failure of combination abacavir + tenofovir + lamivudine (3TC).
AIDS Treat News; 2003 Jul; (393):2. PubMed ID: 14679923
[TBL] [Abstract][Full Text] [Related]
19. Anti-HIV agents. Trying times for tenofovir and abacavir.
TreatmentUpdate; 2003 Oct; 15(6):2-3. PubMed ID: 17216860
[No Abstract] [Full Text] [Related]
20. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
Nishijima T; Komatsu H; Teruya K; Tanuma J; Tsukada K; Gatanaga H; Kikuchi Y; Oka S
AIDS; 2013 Mar; 27(5):839-42. PubMed ID: 23719354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]